Marseille, France, May 7, 2024–(BUSINESS WIRE)–Regulatory news:
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“congenital” or “company), today the Company will hold a conference call on Tuesday, May 14, 2024 at 2:00 PM CET / 8:00 AM EDT to provide an update on the progress of its business in the first quarter of 2024. Announced that information will be released.
The participants in the call are:
-
Hervé Briley, Chief Executive Officer
-
Sonia Quaratino, Executive Vice President and Chief Medical Officer
-
Yannis Morel, Executive Vice President and Chief Operating Officer
-
Frédéric Lombard, Senior Vice President and Chief Financial Officer
-
Arvind Sood, Executive Vice President and President of U.S. Operations
Virtual event details
The live webcast can be viewed at the following link:
https://events.q4inc.com/attendee/244650312
Attendees may also participate by phone using the following registration link: https://registrations.events/direct/Q4I9730892
This information is also available in the Investor section of the Innate Pharma website (www.innate-pharma.com). A replay of the webcast will be available on our website for 90 days after the event.
About Innate Pharma
Innate Pharma SA is a global clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through therapeutic antibodies and its ANKET.® (aantibody-based N.K. cell ENgar Therapeutics) proprietary platform.
Innate's portfolio includes leading proprietary programs racutamab, developed in advanced forms of cutaneous and peripheral T-cell lymphoma, monalizumab, developed with AstraZeneca in non-small cell lung cancer, and ANKET .® Multispecific NK cell engagers to address multiple tumor types.
As a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca and leading research institutions, Innate Pharma accelerates innovation, research and development for the benefit of patients.
Headquartered in Marseille, France, with a U.S. office in Rockville, Maryland, Innate Pharma is listed on Euronext Paris and Nasdaq in the United States.
For more information about Innate Pharma, please visit www.innate-pharma.com. follow me. X And LinkedIn.
Innate Pharma stock information
ISIN code |
FR0010331421 |
|
ticker code |
Euronext: IPH Nasdaq: IPHA |
|
Ray |
9695002Y8420ZB8HJE29 |
Disclaimer Regarding Forward-Looking Information and Risk Factors
This press release contains certain forward-looking statements, including within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words such as “believes,” “may,” “expects,” “will” and similar expressions are intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from expectations. . These risks and uncertainties include uncertainties inherent in research and development, including safety, the progress and results of ongoing and planned clinical trials and preclinical studies, and regulatory review and approval of product candidates. included. our commercialization efforts and our continued ability to obtain development financing; Please see the “Risk Factors” section for additional discussion of risks and uncertainties that may cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements. please refer to. A universal registration document filed with the French Financial Market Authority (“AMF”) (available on the AMF website http://www.amf-france.org or Innate Pharma’s website), and filed with the U.S. Securities Public documents and reports submitted by the Company, including the Company's Annual Report on Form 20-F for the year ended December 31, 2023, and any subsequent public documents filed with the AMF or the SEC or published by the Company. Includes submissions and reports.
This press release and the information contained herein does not constitute an offer to sell, or the solicitation of an offer to buy or subscribe for, any shares of Innate Pharma in any country.
View source version on businesswire.com. https://www.businesswire.com/news/home/20240506536913/ja/
contact address
Investor
Innate Pharma
henry wheeler
Phone number: +33 (0)4 84 90 32 88
Henry.wheeler@innate-pharma.fr
Media contact point
new cap
Arthur Louiet
Phone number: +33 (0)1 44 71 00 15
innate@newcap.eu